Biocon & Equillium https://www.biocon.com/biocon_press_release_20191212.asp
"Biocon & Equillium Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand
BENGALURU, Karnataka, India/ LA JOLLA, Calif. December 12, 2019 –
Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company and Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that they have expanded their collaboration and license agreement for itolizumab to grant Equillium exclusive rights for developing and commercializing itolizumab in Australia and New Zealand.
Equillium had originally secured exclusive rights to develop and commercialize Biocon’s novel biologic, itolizumab, for the U.S. and Canada markets, in May 2017."
Apparently, EQ gets no money from sales in India. And they are way early in their clinical development, unless, I guess, the FDA gives them a Phase III. https://equilliumbio.com/pipeline/#top